Business

XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO™, Targeting USD$700M+ U.S. Gout Market Opportunity

Financial Post · September 18, 2026 at 8:07 a.m.

Investigational New Drug application planned for submission to the U.S.

FDA in the fourth quarter of 2026, advancing the Company’s regulatory path toward NDA filing for gout program XRx-026 CALGARY, Alberta, Sept.

18, 20

Read the full article on Financial Post ›

5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on financialpost.com — the content belongs to Financial Post.

XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO™, Targeting USD$700M+ U.S. Gout Market Opportunity

More from Financial Post

Historic $250 Million Gift from John Paulson to Hebrew University Will Advance Engineering, Medicine, and Trauma Recovery

CGTN: From ‘potato capital’ to ‘token city’: How a city in north China is transforming

The Alberta referendum in focus: FP Video explores

Risk of an AI crunch for stock markets is rising

More in Business

Historic $250 Million Gift from John Paulson to Hebrew University Will Advance Engineering, Medicine, and Trauma Recovery

CGTN: From ‘potato capital’ to ‘token city’: How a city in north China is transforming

The Alberta referendum in focus: FP Video explores

Risk of an AI crunch for stock markets is rising

William Watson: In new pamphlet, U.K.’s Kemi Badenoch points the (right) way

Pipeline, major projects shows Ottawa’s commitment to Alberta, Smith says